Related Experiment Videos
Diabetic nephropathy: from micro- to macroalbuminuria
G Deferrari1, M Repetto, C Calvi
1Department of Internal Medicine, University of Genova, Italy.
Summary
Strict blood pressure control, especially with ACE inhibitors, and maintaining glycosylated hemoglobin below 7.5-8% are key to preventing diabetic nephropathy progression. These interventions play a crucial role in the secondary prevention of kidney failure in diabetic patients.
Area of Science:
- Nephrology
- Endocrinology
- Cardiology
Background:
- Diabetic nephropathy, characterized by microalbuminuria progressing to macroalbuminuria, is a major complication of diabetes mellitus.
- Hyperglycemia and hypertension are recognized as primary drivers of diabetic kidney disease progression.
Purpose of the Study:
- To review the major factors contributing to the progression of diabetic nephropathy.
- To specifically examine the roles of glycemic control and hypertension management in preventing overt nephropathy.
Main Methods:
- Review of experimental and cohort studies on hyperglycemia and diabetic nephropathy.
- Analysis of long-term interventional studies on metabolic control in microalbuminuric patients.
- Examination of cross-sectional and interventional studies on hypertension and antihypertensive therapy in diabetic patients.
Main Results:
- Good metabolic control (HbA1c < 7.5-8%) appears protective against nephropathy development.
- Arterial hypertension is consistently associated with progressive renal damage in both IDDM and NIDDM.
- Antihypertensive therapy, particularly with ACE inhibitors, significantly reduces proteinuria and prevents overt nephropathy.
Conclusions:
- Antihypertensive treatment, especially ACE inhibitors, is vital for secondary prevention of renal failure in diabetic patients.
- Optimal blood pressure targets are suggested around 120/70-75 mmHg for younger and 125-130/80-85 mmHg for older patients.
- While strict metabolic control is fundamental, its impact on preventing overt nephropathy in microalbuminuric patients is less clear than antihypertensive therapy.